1-苄氧羰基哌啶-3-甲酰氯 | 216502-94-2

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄氧羰基哌啶-3-甲酰氯
• 中文别名: 1-CBZ-哌啶-3-甲酰氯；1-苄基丁氧基羰基哌啶-3-羰基氯
• 英文名称: 1-[(benzyloxy)carbonyl]piperidine-3-carbonyl chloride
• 英文别名: 3-chlorocarbonyl-piperidine-1-carboxylic acid benzyl ester；(+/-)-benzyl-3-(chlorocarbonyl)piperidine-1-carboxylate；1-(benzyloxycarbonyl)piperidine-3-carbonyl chloride；benzyl 3-(chlorocarbonyl)piperidine-1-carboxylate；benzyl-3-(chlorocarbonyl)piperidine-1-carboxylate；benzyl 3-carbonochloridoylpiperidine-1-carboxylate
• CAS: 216502-94-2
• 化学式: C₁₄H₁₆ClNO₃
• mdl: MFCD03407318
• 分子量: 281.739
• InChiKey: WVIBCUKTQAQPKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2933399090

SDS

Name:	Benzyl 3-(chlorocarbonyl)tetrahydro-1(2h)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	216502-94-2

Section 1 - Chemical Product MSDS Name:Benzyl 3-(chlorocarbonyl)tetrahydro-1(2h)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
216502-94-2	Benzyl 3-(chlorocarbonyl)tetrahydro-1(	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 216502-94-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Oil
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H16ClNO3
Molecular Weight: 281.74

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 216502-94-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 3-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 216502-94-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 216502-94-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 216502-94-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苄氧羰基哌啶-3-甲酰氯 在 palladium on activated charcoal 吡啶 、 氢气 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 37.5h， 生成
  参考文献：
  名称：

  Synthesis and evaluation of RGD peptidomimetics aimed at surface bioderivatization of polymer substrates

  摘要：

  Several RGD peptidomimetics have been prepared, in a convergent way, from the common ortho-amino-tyrosine template (O-substituted with an anchorage-arm or a methyl group, and alpha N-substituted with a fluorine tag for XPS analysis), and various omega-aminoacid derivatives. The most flexible compounds have shown a biological activity similar to that of the peptide reference (RGDS) in the platelet aggregation test. The compound 16a could be fitted (by modelisation) with DMP 728 and c(RGDfV), two cyclic peptides that are good ligands of integrins. The compound 16b has been covalently fixed on the surface of a poly(ethylene terephthalate) membrane used as support for mammalian cell cultivation. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)00083-2
• 作为产物：
  描述：

  3-哌啶甲酸 在 sodium hydroxide 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 1-苄氧羰基哌啶-3-甲酰氯
  参考文献：
  名称：

  CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological evaluation of piperidine-4-carboxamide derivatives

  摘要：

  Replacement of the 5-oxopyrrolidin-3-yl fragment in the previously reported lead structure with a 1-acetylpiperidin-4-yl group led to the discovery of a novel series of potent CCR5 antagonists. Introduction of small hydrophobic substituents on the central phenyl ring increased the binding affinity, providing low to sub-nanomolar CCR5 antagonists. The selected compound 11f showed excellent antiviral activity against CCR5-using HIV-1 replication in human peripheral blood mononuclear cells (EC50 = 0.59 nM) and an acceptable pharmacokinetic profile in dogs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.10.013

文献信息

• Synergistic Visible-Light Photoredox/Nickel-Catalyzed Synthesis of Aliphatic Ketones via N–C Cleavage of Imides
  作者：Javad Amani、Rauful Alam、Shorouk Badir、Gary A. Molander

  DOI：10.1021/acs.orglett.7b00989

  日期：2017.5.5

  An electrophilic, imide-based, visible-light-promoted photoredox/Ni-catalyzed cross-coupling reaction for the synthesis of aliphatic ketones has been developed. This protocol proceeds through N–C(O) bond activation, made possible through the lower activation energy for metal insertion into this bond due to delocalization of the lone pair of electrons on the nitrogen by electron-withdrawing groups.

  开发了一种用于合成脂肪酮的亲电、酰亚胺基、可见光促进的光氧化还原/镍催化交叉偶联反应。该协议通过 N-C(O) 键激活进行，由于吸电子基团使氮上的孤对电子离域，金属插入该键的激活能较低，从而使金属插入该键成为可能。交叉偶联反应操作简单且温和，在环境温度下进行，并且对多种官能团表现出耐受性。
• [EN] INHIBITORS OF PROTEIN KINASES<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：INGENIUM PHARMACEUTICALS GMBH

  公开号：WO2009047359A1

  公开（公告）日：2009-04-16

  Compounds of general Formula I, wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

  通式I的化合物，其中R1、R2、R3、x、A和Ra的定义如本文所述，是细胞周期依赖性激酶的抑制剂，可用于预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病。
• BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
  申请人：Chu Daniel

  公开号：US20090197863A1

  公开（公告）日：2009-08-06

  A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R 1 , R 2 , R 3 , and R 4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

  具有以下式(I)或式(II)所示结构的化合物： 其中变量Y，R1，R2，R3和R4如本文所定义。本文提供了聚(ADP-核糖)聚合酶活性的抑制剂。本文还描述了包括至少一种本文描述的化合物的药物组合物，以及使用本文描述的化合物或药物组合物治疗通过抑制PARP活性改善的疾病、疾病和症状。
• 1-heterocyclic bicyclo-octanes
  申请人：The Wellcome Foundation Limited

  公开号：US05057504A1

  公开（公告）日：1991-10-15

  Pesticidal bicyclo-octanes are of the formula ##STR1## where R is a substituted or unsubstituted aliphatic or aromatic group, R' and R.sup.3 are H or a substituted or unsubstituted aliphatic or aromatic group, R.sup.2 is a substituted or unsubstituted heterocyclic group containing at least one ring nitrogen and is preferably a 3- or 4- pyridyl group, Z is CH.sub.2 CH.sub.2, CH.sub.2 O--CH.sub.2 S or COCH.sub.2 or CH(OR.sup.5)CH.sub.2 where R.sup.5 is H, alkyl, acyl or carbamoyl at Y and Y' are O or S(O).sub.m where m is 0, 1 or 2. Various methods for their preparation are described.

  杀虫双环辛烷的化学式为##STR1##其中R是取代或未取代的脂肪族或芳香族基团，R'和R.sup.3是H或取代或未取代的脂肪族或芳香族基团，R.sup.2是含有至少一个环氮的取代或未取代的杂环基团，最好是3-或4-吡啶基团，Z是CH.sub.2 CH.sub.2，CH.sub.2 O-CH.sub.2 S或COCH.sub.2或CH(OR.sup.5)CH.sub.2，其中R.sup.5是H、烷基、酰基或碳酰基，在Y和Y'处为O或S(O).sub.m，其中m为0、1或2。描述了它们的各种制备方法。
• [EN] ISOQUINOLINONE POTASSIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS DU CANAL POTASSIQUE A BASE D'ISOQUINOLINONE
  申请人：MERCK & CO INC

  公开号：WO2005030726A1

  公开（公告）日：2005-04-07

  The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

  本发明涉及具有结构（I）的化合物，用作钾通道抑制剂，用于治疗心律失常等。